0.00
0.00%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Zyversa Therapeutics
Its shares trade under the ticker ZVSA. It has been listed since 21 December 2021.
Zyversa Therapeutics Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Weston, Florida. The company went IPO on 2021-12-21. ZyVersa Therapeutics, Inc. is a clinical-stage specialty biopharmaceutical company. The firm is focused on leveraging advanced technologies to develop drugs for patients with chronic renal or inflammatory diseases. Its development pipeline includes a renal drug candidate, namely VAR 200 (2-hydroxypropyl-beta-cyclodextrin or 2HPβCD), a cholesterol efflux mediator for the treatment of a rare kidney disease, focal segmental glomerulosclerosis. Its VAR 200 has the potential to treat other glomerular diseases, including alport syndrome and diabetic kidney disease. Its lead indication for VAR 200 is focal segmental glomerulosclerosis (FSGS). The firm's development pipeline also includes an anti-inflammatory drug candidate, namely IC 100, an inflammasome ASC inhibitor being developed to treat a multitude of inflammatory diseases. Its renal product candidate, VAR 200, mediates the removal of excess intracellular lipids that contribute to kidney damage and lead to end-stage renal disease.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 21 Dec 2021
- Employees
- 7
- Website
- zyversa.com ↗
- Head office
- 2436 NORTH FEDERAL HIGHWAY, LIGHTHOUSE POINT, FL, 33064
- Incorporated in
- DE
- Classification
- Pharmaceutical Preparations
- Filer status
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Leadership
Pay as last reported
- Mr. Stephen GloverChairman of the Board, President, Chief Executive Officer, Co-Founder, since 2022$550,000
- Mr. Peter WolfeChief Financial Officer, Secretary$395,000
- Mr. Pablo GuzmanChief Medical Officer, Senior Vice President - Medical Affairs$350,000
- Ms. Karen CashmereChief Commercial Officer$486,687
- Mr. Robert FinizioIndependent Director$63,000
- Mr. Gregory FreitagIndependent Director$62,500
- Dr. Min Chul ParkIndependent Director$51,500
- Mr. James SapirsteinIndependent Director$63,500
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Zyversa Therapeutics Inc operates in the US biotechnology sector with 7 employees.
- VAR 200 targets focal segmental glomerulosclerosis, a rare kidney disease.
- IC 100 is an anti-inflammatory drug candidate for multiple diseases.
Weaknesses
- The company has only 7 full-time employees as of the listing date.
- VAR 200 is still in the clinical development pipeline stage.
- IC 100 is an early-stage inflammasome ASC inhibitor candidate.
Opportunities
- VAR 200 has potential to treat alport syndrome and diabetic kidney disease.
- The firm leverages advanced technologies for chronic renal disease treatments.
- VAR 200 mediates removal of lipids contributing to kidney damage.
Threats
- VAR 200 faces competition in the rare kidney disease market.
- IC 100 must prove efficacy against multiple inflammatory diseases.
- Regulatory hurdles exist for clinical-stage biopharmaceutical drug candidates.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.